Literature DB >> 9038176

Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a).

D K Bonen1, A M Hausman, C Hadjiagapiou, S F Skarosi, N O Davidson.   

Abstract

Apolipoprotein(a) (apo(a)), a large glycoprotein with extensive homology to plasminogen, forms a complex with apolipoprotein B100 (apoB100), which circulates in human plasma in the form of lipoprotein(a) (Lp(a)). Evidence indicates that the association of apo(a) with apoB100 occurs in the extracellular environment. We have reevaluated the possibility that apo(a)-B100 association can also occur as an intracellular event through studies with HepG2 cells stably transfected with an apo(a) minigene. Several lines of evidence support this possibility. First, continued Lp(a) production was demonstrated following incubation of transfected HepG2 cells with anti-apo(a) antisera, conditions that effectively block the fluid-phase association of apo(a) and apoB100 in vitro. Second, an apo(a)-B100 complex was detectable in Western blot analyses of transfected HepG2 lysates following immunoprecipitation with anti-apo(a) antisera. These studies incorporated precautions to eliminate cell-surface attachment of preformed apo(a)-B100 complexes to the low density lipoprotein receptor and were conducted in the presence of the lysine analog epsilon-aminocaproic acid, which precludes apo(a)-B100 association occurring during the isolation and analyses. Third, the presence of an intracellular apo(a)-B100 complex was demonstrated in lipoproteins isolated from microsomal contents. Of particular significance was the observation that this complex contained the precursor form of apo(a), which is not secreted, in addition to the mature, recombinant form. Finally, direct evidence was provided for the synthesis of a precursor form of apo(a) in a nascent intracellular complex with apoB100 following treatment of transfected HepG2 cells with brefeldin A plus N-acetyl-leucyl-leucyl-norleucinal. Taken together, these data suggest that apo(a)-B100 association can occur as an intracellular event in a human hepatoma-derived cell line, raising important implications for the regulation of Lp(a) secretion from human liver.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038176     DOI: 10.1074/jbc.272.9.5659

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 2.  Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Tina Tran; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2011-07-12       Impact factor: 1.894

3.  Enigmatic role of lipoprotein(a) in cardiovascular disease.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Lars Berglund
Journal:  Clin Transl Sci       Date:  2010-12       Impact factor: 4.689

4.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

5.  Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.

Authors:  Menggui Huang; Yanqing Gong; Jessica Grondolsky; Jane Hoover-Plow
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

Review 6.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

Review 7.  Lipoprotein (a): When to Measure and How to Treat?

Authors:  David Rhainds; Mathieu R Brodeur; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2021-07-08       Impact factor: 5.113

8.  FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway.

Authors:  Xiaolong Lin; Guohua Li; Xinglan He; Xiaofeng Ma; Kai Zhang; Hai Zhang; Gaofeng Zeng; Zuo Wang
Journal:  Mol Cell Biochem       Date:  2014-04-04       Impact factor: 3.396

Review 9.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

Review 10.  Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

Authors:  Anping Cai; Liwen Li; Ying Zhang; Yujin Mo; Weiyi Mai; Yingling Zhou
Journal:  Dis Markers       Date:  2013-10-22       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.